{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-24-000116","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.667541+00:00","generated_at":"2026-06-03T04:58:45.637453+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lilly Q1 revenue up 26% to $8.77B; raises full-year guidance by $2B","bullets":["Q1 reported EPS $2.48 (up 66% YoY); non-GAAP EPS $2.58 (up 59% YoY), including $0.10 acquired IPR&D charges.","Revenue $8.77B, driven by Mounjaro, Zepbound, Verzenio, Jardiance; raised FY2024 revenue guidance by $2.0B.","Raises FY2024 reported EPS guidance to $13.05-$13.55 and non-GAAP EPS to $13.50-$14.00.","Pipeline progress: positive Phase 3 tirzepatide for OSA, mirikizumab submission for Crohn's, lebrikizumab resubmission.","Agreement to acquire injectable medicine manufacturing facility from Nexus Pharmaceuticals; broke ground on $2.5B German site."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-24-000116","json":"https://secwatch.observer/filing/0000059478-24-000116.json","markdown":"https://secwatch.observer/filing/0000059478-24-000116.md","text":"https://secwatch.observer/filing/0000059478-24-000116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947824000116/0000059478-24-000116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947824000116/lly-20240430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T04:58:45.637453+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07856b6cd4f97bf689c18ac29b3b3ede725165c3","claim":"ELI LILLY & Co reported first quarter of 2024 results: revenue $8,768.0, net income $2,242.9, EPS $2.48. Guidance raised.","evidence_excerpt":"on important public announcements, visit the news section of Lilly's website. Financial Results $ in millions, except per share data First Quarter 2024 2023 % Change Revenue $ 8,768.0 $ 6,960.0 26% Net income – Reported 2,242.9 1,344.9 67% Earnings per share – Reported 2.48 1.49 66% Net income – Non-GAAP 2,335.3 1,463.9 60% Earnings per share – Non-GAAP 2.58","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/59478/000005947824000116/0000059478-24-000116-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Revenue","value":"$8,768.0"},{"label":"Net income","value":"$2,242.9"},{"label":"EPS","value":"$2.48"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}